Inogen (INGN)
(Delayed Data from NSDQ)
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
Cantel Medical (CMD) Q2 Earnings & Sales Grow Year Over Year
by Zacks Equity Research
Cantel Medical Corp. (CMD) reported adjusted earnings of 52 cents per share in the second quarter of fiscal 2017.
Medtronic Initiates BTK Study on DCB for PAD Cure in Europe
by Zacks Equity Research
Medtronic plc (MDT) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon for treatment of peripheral arterial disease (PAD).
Humana's Subsidiaries Receive Rating Action from A.M. Best
by Zacks Equity Research
Humana Inc. (HUM) recently received rating action from A.M. Best. The rating giant has removed from under review, with positive implications, the majority of insurance subsidiaries of the company.
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
UnitedHealth's Senior Unsecured Notes Rated by A.M Best
by Zacks Equity Research
UnitedHealth Group, Inc.'s (UNH) senior unsecured notes recently received rating action from A.M Best.
Earnings Estimates Moving Higher for Inogen (INGN): Time to Buy?
by Zacks Equity Research
Inogen (INGN) has seen positive earnings estimate revisions for the current quarter and year, in addition to decent short-term price momentum.
VWR Corporation (VWR): Q4 Lacks Shine, Currency Woes Remain
by Zacks Equity Research
On Mar 9, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR) -- a global provider of products, services and solutions to laboratory and production facilities.
4 Big Winners of Trump's Healthcare Plan
by Swarup Gupta
The new healthcare legislation has its own sets of winners and losers.
3 Reasons Why Inogen (INGN) is a Great Momentum Stock
by Zacks Equity Research
Let's focus on Inogen, Inc. (INGN) as this momentum stock is looking especially impressive right now.
Walgreens Boots Grapples with Headwinds: Should You Dump?
by Zacks Equity Research
On Mar 8, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise Walgreens Boots Alliance, Inc. (WBA).
Community Health Prices Senior Secured Notes Worth $2.2B
by Zacks Equity Research
Community Health Systems, Inc. (CYH) recently announced that it has issued 6.25%, $2.2 billion Senior Secured Notes, due 2023. The offering was upsized by $450 million.
CVS Health Adopts Epic EHR for Specialty Care Programs
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced that it has chosen Epic as the electronic health record (EHR) system for CVS Specialty's care management programs.
BioScrip (BIOS): Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
BioScrip, Inc. (BIOS) reported net loss from continuing operations of $5.2 million or loss of 6 cents per share in the fourth quarter of 2016, much narrower than the year-ago net loss of $16.9 million or loss of 28 cents.
Inogen (INGN) Tops Earnings & Revenues in Q4; View Upbeat
by Zacks Equity Research
Inogen Inc. (INGN) reported fourth-quarter 2016 earnings of 25 cents per share, which surpassed both the Zacks Consensus Estimate by 15 cents and the year-ago figure by 11 cents.
athenahealth (ATHN) Beats on Q4 Earnings, Misses Revenues
by Zacks Equity Research
athenahealth (ATHN) reported adjusted earnings of 42 cents per share, which beat the Zacks Consensus Estimate of 27 cents.
PerkinElmer (PKI) Misses Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Waltham, MA-based PerkinElmer Inc (PKI) reported fourth-quarter 2016 earnings of 83 cents per share missing the Zacks Consensus Estimate of 86 cents
CONMED (CNMD) Q4 Earnings Miss Estimates, Increase Y/Y
by Zacks Equity Research
Headquartered in Utica, NY, leading medical technology player, CONMED Corporation (CNMD) reported fourth-quarter 2016 adjusted earnings of 54 cents per share, missing the Zacks Consensus Estimate by 2 cents.
Baxter International (BAX) Q4 Earnings Beat, Revenues Lag
by Zacks Equity Research
Baxter International Inc. (BAX) reported fourth-quarter 2016 adjusted earnings of 57 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and were well above the year-ago figure of 43 cents.
Glaukos (GKOS) Catches Eye: Stock Adds 5.6% in Session
by Zacks Equity Research
Glaukos Corporation (GKOS) moved big last session, as its shares jumped almost 6% on the day.
Inogen (INGN) Affirms Outlook and Shuffles Top Management
by Zacks Equity Research
Inogen, Inc. (INGN) reiterated its fiscal 2016 outlook and appointed a new President cum Chief Executive Officer.
Top Stocks with Big Potential Catch-Up Moves
by Kevin Matras
Given the recent run-up in the market, here's a screen I've been using recently. Highlighted stocks include CSGP, CW, HLS, INGN and PKI.